About this Journal Submit a Manuscript Table of Contents

PPARs and Metabolic Syndrome

Call for Papers

Metabolic syndrome is a cluster of metabolic abnormalities, including insulin resistance, glucose intolerance, obesity, hypertension, and dyslipidemia. People with metabolic syndrome have increased risks to develop type 2 diabetes, stroke, and cardiovascular diseases. The pathophysiologic mechanism underlying metabolic syndrome involves a complex interaction of crucial factors. Accumulating evidence suggests that metabolic nuclear receptors including peroxisome proliferator-activated receptors (PPARs) play important roles in metabolic syndrome. Many PPAR agonists have been used for the treatment of metabolic syndrome and the related complications. Activation of PPARs increases insulin sensitivity, reduces blood glucose, lowers blood pressure, decreases circulating lipids, and attenuates atherosclerosis in both human and mouse models.

In this special issue, we would like to invite authors to submit original research articles as well as review articles that focus on understanding the relationship between PPAR family and metabolic syndrome. Potential topics include, but are not limited to:

  • PPARs and type 2 diabetes and diabetic nephropathy
  • PPARs and obesity
  • PPARs and dyslipidemia
  • PPARs and blood pressure regulation
  • PPARs and atherosclerosis and other cardiometabolic diseases
  • Genetic polymorphisms of PPARs and metabolic diseases
  • Potential therapies of PPAR ligands for metabolic syndrome
  • Toxicology and clinical safety profile of PPAR ligands

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/ppar/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/ppar/meta/ according to the following timetable:

Manuscript DueFriday, 25 October 2013
First Round of ReviewsFriday, 17 January 2014
Publication DateFriday, 14 March 2014

Lead Guest Editor

  • Lihong Chen, Institute for Translational Medicine and Therapeutics, Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA

Guest Editors

  • Zhanjun Jia, Division of Nephrology and Hypertension, University of Utah, Salt Lake City, UT, USA
  • Guangrui Yang, Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA